Genprex announced the formation of a Mesothelioma Clinical Advisory Board to support the company’s preclinical mesothelioma oncology program. The Board is comprised of four world-renown researchers from major research institutions specializing in the treatment of mesothelioma.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNPX:
- Biotech Alert: Searches spiking for these stocks today
- Genprex plans to launch separate company to focus on gene therapy
- Genprex provides clinical study updates for its Acclaim 1 and 3 trials
- Genprex granted patent in Singapore for Reqorsa gene therapy
- Genprex price target lowered to $7.50 from $8 at Alliance Global Partners